MediPharm Labs Corp.
LABS.TO
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -18.77% | -4.54% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.77% | -4.54% | |||
| Cost of Revenue | -21.93% | -19.43% | |||
| Gross Profit | -12.75% | 47.52% | |||
| SG&A Expenses | -1.54% | -4.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -100.55% | 87.17% | |||
| Total Operating Expenses | -17.02% | -12.85% | |||
| Operating Income | -3.06% | 56.34% | |||
| Income Before Tax | 55.83% | 9.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 55.83% | 9.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 55.83% | 9.23% | |||
| EBIT | -3.06% | 56.34% | |||
| EBITDA | -7.36% | 67.76% | |||
| EPS Basic | 54.55% | 10.81% | |||
| Normalized Basic EPS | 10.00% | 56.52% | |||
| EPS Diluted | 54.55% | 10.81% | |||
| Normalized Diluted EPS | 10.00% | 56.52% | |||
| Average Basic Shares Outstanding | 0.75% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.75% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||